Progesterone and Prolactin

sethroberts

sethroberts

Active member
Awards
1
  • Established
You have some interesting theory’s and I can agree with most of what you are saying, but I have to make it clear to the members that there other point of views on this subject… simply because I have a vested interest that my customer don’t have gyno symptoms when using our products.
I don't mean to be crabby, but my "interesting theory's" are built on 19+ years of personal experience combined with an extensive knowledge of physiology and pharmacology as well as 10+ years in the lab so when someone comes along asserting somethign to be fact based on personal experience alone and question my knowledge, I get a little miffed.

quotes like this one "If you are referring to a stimulus effect at the female hypothalamus/pituitary of estrogen or progesterone, I hope you’re not assuming this stimulatory effect applies to males." don't help.
 
crazyfool405

crazyfool405

Banned
Awards
1
  • Established
your previous quote:
i was on epi as well as npp, and test, i stopped the epi and im still on npp and test and within 24 hours, my gyno came back

Ok, you said you were on epi, mpp and test you stopped epi and within 24 hours gyno came back, so this was three months after what?
alright ill give you the scoop lol ill just post it all in here,

i ran PPlex mdrol bridge as you know and i ended up geting gyno about 1 week before my next cycle which was and still is....


My History and current status
For all of you who have followed my previous log you know whats going on. I havent posted in there for a while so im going to start a discussion, not a flame, nothing of the sort but explain what i did (which you should not do), and the current stack i am doing

History: (here goes another one thread)

Week 1-5 test E 500mg
Week 6-12 .6 mL ST450 (260mg), 1.4mL Test E (350mg)
Week 12-17 .6mL ST450 (260mg), 1.4mL Test C (350mg), 3mL NPP (300mg)
Week 18-25/26 .6mL ST450 (260mg), 1.4mL Test C (350mg), 2 mL Tren A (200mg)
week 1-3 EQT2 (3 caps)
week 3-5 Hdrol (3 caps)
week 2-5 Trenadrol (2/2/3/3)
Week 10-13 Epithin E (3/3/3/4)


ob viously long yadda yadda, i know how everyone will react, im going from bulk to cut....

i havent started tren yet
 
sethroberts

sethroberts

Active member
Awards
1
  • Established
alright ill give you the scoop lol ill just post it all in here,

i ran PPlex mdrol bridge as you know and i ended up geting gyno about 1 week before my next cycle which was and still is....


My History and current status
For all of you who have followed my previous log you know whats going on. I havent posted in there for a while so im going to start a discussion, not a flame, nothing of the sort but explain what i did (which you should not do), and the current stack i am doing

History: (here goes another one thread)

Week 1-5 test E 500mg
Week 6-12 .6 mL ST450 (260mg), 1.4mL Test E (350mg)
Week 12-17 .6mL ST450 (260mg), 1.4mL Test C (350mg), 3mL NPP (300mg)
Week 18-25/26 .6mL ST450 (260mg), 1.4mL Test C (350mg), 2 mL Tren A (200mg)
week 1-3 EQT2 (3 caps)
week 3-5 Hdrol (3 caps)
week 2-5 Trenadrol (2/2/3/3)
Week 10-13 Epithin E (3/3/3/4)


ob viously long yadda yadda, i know how everyone will react, im going from bulk to cut....

i havent started tren yet
so you got gyno while you were still on the bridge it went away on the EQT2 and then when you went off it came back? Sorry -- difficult to follow
 
crazyfool405

crazyfool405

Banned
Awards
1
  • Established
so you got gyno while you were still on the bridge it went away on the EQT2 and then when you went off it came back? Sorry -- difficult to follow
got gyno 1 week before EQT2, treated with adex through my cycle up until epithin E, (5a reduced has an atangonist effect on e2 from what i read mild AI prop) and within 1 day of stopping it, it came back full force, now im treating again with adex,

hope that cleared it up

BTW you need anyguinie pigs to help do any studies lol im down
 
mooch2321

mooch2321

Well-known member
Awards
1
  • Established
yeah...i cant really keep up either crazy....
 
sethroberts

sethroberts

Active member
Awards
1
  • Established
got gyno 1 week before EQT2, treated with adex through my cycle up until epithin E, (5a reduced has an atangonist effect on e2 from what i read mild AI prop) and within 1 day of stopping it, it came back full force, now im treating again with adex,

hope that cleared it up

BTW you need anyguinie pigs to help do any studies lol im down
Clears it up for me I think. It seems to be nothing outside of normal estrogen related gyno. The phera and superdrol suppresss SHBG levels freeing up estradiol and estrone as well as removing the protective effect of SHBG and probably stimulating DHEA production in the adrenal which can have some estrogneic activity of its own without conversion. So this initiated the gyno one week before starting. the epithiostanol probably has some AI ability but likely also acts as an estrogen receptor antagonist which is why you saw symptoms as soon as you went off. The AI will help with the production of estrogen, but it does nothing for the circulating pool of estrogen, especially in the form of estrone sulfate which can be very long lived.
 
crazyfool405

crazyfool405

Banned
Awards
1
  • Established
Clears it up for me I think. It seems to be nothing outside of normal estrogen related gyno. The phera and superdrol suppresss SHBG levels freeing up estradiol and estrone as well as removing the protective effect of SHBG and probably stimulating DHEA production in the adrenal which can have some estrogneic activity of its own without conversion. So this initiated the gyno one week before starting. the epithiostanol probably has some AI ability but likely also acts as an estrogen receptor antagonist which is why you saw symptoms as soon as you went off. The AI will help with the production of estrogen, but it does nothing for the circulating pool of estrogen, especially in the form of estrone sulfate which can be very long lived.
soo some I3C later on can help in that area right>
 
mooch2321

mooch2321

Well-known member
Awards
1
  • Established
so in crazy's case seth would you recomend a combination like adex/nolva in low doses?...or something elase entirely
 
Problem

Problem

Member
Awards
1
  • Established
I would caution against "reducing" estrogen as I do think that AIs may be partially to blame. "Controlling" estrogen is preferable and I am partial to SERMS for this purpose. Especially for non-aromatizing or low aromatizing compounds because the reduction in SHBG and the increased "free" estrogens will not be helped by AI's.
I got 2 small lumps under my nipple after a month of my PCT using Nolvadex. (cycle was tren/hdrol) I never been prone to gyno nor had it before. I have no clue what happened, but i just came up with my own conclusion that estrogen elevated again...

So you think if i used a low dose of AI after i stopped that SERM would have brought me different results?
 
sethroberts

sethroberts

Active member
Awards
1
  • Established
People started invoking "new" mechanisms for the induction of gyno in the late 1990's -- As far as I know, I was one of the first people proposing progesterone receptor activation as a potential cause of gyno back then. I have changed my mind since then as I have accumulated knowledge over the years. There is no evidence that progesterone or prolactin intitiate gynecomastia but plenty of evidence that estrogen does. All of this stemmed fro mthe fact that people were complaining of gyno from anadrol but also fron tren and nandrolone none of which were supposed to convert to estrogen. What I realized a while ago is that there is no need to invoke exotic mechanisms. Pher and superdrol do not convert to estrogen (nor does tren or anadrol) but they do suppress SHBG. SHBG is actually protective against breast tissue growth beyond just sequestering estrogens (you can read more about this in my book ;)). The removal of this protective effect as weel as the increase in "free" estrogen from the reduction in SHBG can explain some of the propensity for forming gyno with these compounds. With nandrolone, trenbolone, and other 19-norsteroids, there is also the added production of 5-alpha reduced metabolites that are weak androgens (there is some evidence that tren is metabolized in this fashion) which upstes the androgen to estrogen rati and further contributes to the ability to produce gyno.
 
sethroberts

sethroberts

Active member
Awards
1
  • Established
so in crazy's case seth would you recomend a combination like adex/nolva in low doses?...or something elase entirely
I am not a fan of AIs - they tend to suppress estrogen too low and SHBG with it not to mention the effects on cholesterol etc.

In that situation, I would probably have used nolva throughout and into PCT.
 
animaleater2

animaleater2

New member
Awards
0
When I was on a sust/deca cycle I had some first signs of gyno like symptoms. Note I say signs as there were never a lump or discharge that developed. What I do know is that nolva took care of ALL of the symptoms in quick fashion. I also used it along with clomid for pct. This was a year ago and never had issue since.

That said I am week 3 into m-drol cycle and am using a-dex at very low dose and am taking low dose vitex and am have zero sensations in nipple area. I make sure bodyfat is always below 12 percent before starting any cycle as I think this helps.

Just shows that there are a few ways to skin a cat.
 
crazyfool405

crazyfool405

Banned
Awards
1
  • Established
what about the study showing nolva causes sperm damage? im still young when i recover i dont want that to recover and have poor sperm
 
sethroberts

sethroberts

Active member
Awards
1
  • Established
I got 2 small lumps under my nipple after a month of my PCT using Nolvadex. (cycle was tren/hdrol) I never been prone to gyno nor had it before. I have no clue what happened, but i just came up with my own conclusion that estrogen elevated again...

So you think if i used a low dose of AI after i stopped that SERM would have brought me different results?
You may have needed a longer course of nolva since your SHBG levels probably had not recovered by the time you came off. I doubt an AI would have helped since it was probably not production of estrogen that was the problem. I generally believe that 20 mg of nolva is enough but there are circumstances where 40 or 60 mg would be appropriate. These strong androgen cycles are sometimes worst than aromatizing androgens because they can suppress SHBG levels so low.
 
sethroberts

sethroberts

Active member
Awards
1
  • Established
what else can lower estrone sulfate levels....
a sulfotransferase inhibitor or a 17 beta hydroxysteroid dehydrogenase inhibitor to prevent the back conversion of estrone to estradiol -- both of which are in development for breast cancer.
 
Frank Reynolds

Frank Reynolds

Board Supporter
Awards
1
  • Established
People started invoking "new" mechanisms for the induction of gyno in the late 1990's -- As far as I know, I was one of the first people proposing progesterone receptor activation as a potential cause of gyno back then. I have changed my mind since then as I have accumulated knowledge over the years. There is no evidence that progesterone or prolactin intitiate gynecomastia but plenty of evidence that estrogen does. All of this stemmed fro mthe fact that people were complaining of gyno from anadrol but also fron tren and nandrolone none of which were supposed to convert to estrogen. What I realized a while ago is that there is no need to invoke exotic mechanisms. Pher and superdrol do not convert to estrogen (nor does tren or anadrol) but they do suppress SHBG. SHBG is actually protective against breast tissue growth beyond just sequestering estrogens (you can read more about this in my book ;)). The removal of this protective effect as weel as the increase in "free" estrogen from the reduction in SHBG can explain some of the propensity for forming gyno with these compounds. With nandrolone, trenbolone, and other 19-norsteroids, there is also the added production of 5-alpha reduced metabolites that are weak androgens (there is some evidence that tren is metabolized in this fashion) which upstes the androgen to estrogen rati and further contributes to the ability to produce gyno.
I wonder about all these people claiming gyno while using Nolva, and how this would all change if people used PHARM GRADE medicines rather then these research chems.
 
sethroberts

sethroberts

Active member
Awards
1
  • Established
When I was on a sust/deca cycle I had some first signs of gyno like symptoms. Note I say signs as there were never a lump or discharge that developed. What I do know is that nolva took care of ALL of the symptoms in quick fashion. I also used it along with clomid for pct. This was a year ago and never had issue since.

That said I am week 3 into m-drol cycle and am using a-dex at very low dose and am taking low dose vitex and am have zero sensations in nipple area. I make sure bodyfat is always below 12 percent before starting any cycle as I think this helps.

Just shows that there are a few ways to skin a cat.
That is true and it is true that in men the majority of aromatase activity comes from adipose (but not all). I am concerned that opamine manipulation may be contributing to the increased incidence of "gyno" and "lactating" though.
 
sethroberts

sethroberts

Active member
Awards
1
  • Established
what about the study showing nolva causes sperm damage? im still young when i recover i dont want that to recover and have poor sperm
It also inhibits cholesterol side chain cleavage. Don't you think androgens have the potential to cause sperm damage. There are risks involeved to using all of these medications.
 
sethroberts

sethroberts

Active member
Awards
1
  • Established
I wonder about all these people claiming gyno while using Nolva, and how this would all change if people used PHARM GRADE medicines rather then these research chems.
Very good point. Even the "legal" OTC stuff has the potential to be contaminated. How many of these cases of tren gyno are the result of contamination or substitution?
 
crazyfool405

crazyfool405

Banned
Awards
1
  • Established
It also inhibits cholesterol side chain cleavage. Don't you think androgens have the potential to cause sperm damage. There are risks involeved to using all of these medications.
o of course!!! but in recovery i dont want to be damaging my sperm i did enough on cycle.
 
tyler4

tyler4

Active member
Awards
1
  • Established
This thread is very informative and confusing at the same time. There are so many different theories that once you think you have a good understanding on how to prevent certain things, you read a different (yet still legit) opinion.
 
sethroberts

sethroberts

Active member
Awards
1
  • Established
o of course!!! but in recovery i dont want to be damaging my sperm i did enough on cycle.
It's funny. I never worried about sperm damage. That is not to say that it can't happen but sperm are made constantly and I had 3 kids without issue.
 
crazyfool405

crazyfool405

Banned
Awards
1
  • Established
It's funny. I never worried about sperm damage. That is not to say that it can't happen but sperm are made constantly and I had 3 kids without issue.
congrats man!

when i get married thats the number im shooting for .
 
Eric Potratz

Eric Potratz

Board Sponsor
Awards
1
  • Established
1: J Agric Food Chem. 2001 May;49(5):2472-9. Links
Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms.Liu J, Burdette JE, Xu H, Gu C, van Breemen RB, Bhat KP, Booth N, Constantinou AI, Pezzuto JM, Fong HH, Farnsworth NR, Bolton JL.
Department of Medicinal Chemistry and Pharmacognosy, UIC/NIH Center for Botanical Dietary Supplements Research, College of Pharmacy, M/C 781, University of Illinois at Chicago, 833 South Wood Street, Chicago, Illinois 60612, USA.

Eight botanical preparations that are commonly used for the treatment of menopausal symptoms were tested for estrogenic activity. Methanol extracts of red clover (Trifolium pratense L.), chasteberry (Vitex agnus-castus L.), and hops (Humulus lupulus L.) showed significant competitive binding to estrogen receptors alpha (ER alpha) and beta (ER beta). With cultured Ishikawa (endometrial) cells, red clover and hops exhibited estrogenic activity as indicated by induction of alkaline phosphatase (AP) activity and up-regulation of progesterone receptor (PR) mRNA. Chasteberry also stimulated PR expression, but no induction of AP activity was observed. In S30 breast cancer cells, pS2 (presenelin-2), another estrogen-inducible gene, was up-regulated in the presence of red clover, hops, and chasteberry. Interestingly, extracts of Asian ginseng (Panax ginseng C.A. Meyer) and North American ginseng (Panax quinquefolius L.) induced pS2 mRNA expression in S30 cells, but no significant ER binding affinity, AP induction, or PR expression was noted in Ishikawa cells. Dong quai [Angelica sinensis (Oliv.) Diels] and licorice (Glycyrrhiza glabra L.) showed only weak ER binding and PR and pS2 mRNA induction. Black cohosh [Cimicifuga racemosa (L.) Nutt.] showed no activity in any of the above in vitro assays. Bioassay-guided isolation utilizing ER competitive binding as a monitor and screening using ultrafiltration LC-MS revealed that genistein was the most active component of red clover. Consistent with this observation, genistein was found to be the most effective of four red clover isoflavones tested in the above in vitro assays. Therefore, estrogenic components of plant extracts can be identified using assays for estrogenic activity along with screening and identification of the active components using ultrafiltration LC-MS. These data suggest a potential use for some dietary supplements, ingested by human beings, in the treatment of menopausal symptoms.

1: Pak J Biol Sci. 2007 Jul 15;10(14):2300-7.Links
The effects of Vitex agnus castus extract and its interaction with dopaminergic system on LH and testosterone in male mice.Nasri S, Oryan S, Rohani AH, Amin GR.
Department of Biology, Parand Branch, Azad University, Tehran, Iran.

The purpose of this study was to evaluate the probable effects of Vitex agnus castus (Vac.) on the male reproductive physiology. It is a well known fact that LH secretion from the anterior pituitary of mammals is controlled by many neurotransmiters such as dopamine. In this experiment, we have studied the effect of Vac. extract on the LH and testosterone hormones and its interaction with the dopaminergic system on male mice. In order to evaluate these effects, we used the hydroalcoholic Vac. extract (for extraction we used percolation technique) injection with the following doses: 65, 165, 265, 365 and 465 mg kg-', bromocriptine as a dopamine receptor agonist (5, 10, 20 mg kg(-1)) and haloperidol as a dopamine receptor antagonist (1, 1.5, 2, 2.5, 3 mg kg(-1)). To study the interaction between Vac. extract and dopaminergic system, we injected the optimum doses of Vac. with bromocriptine or haloperidol at the same time. Intraperitoneal injections were applied in all experiments, once a day for 30 days. The control group remained intact and the sham group received vehicle. After the last injection, we collected the animal blood serums for hormonal assays. LH and testosterone were measured by Radio Immuno Assay (RIA). LH and testosterone, showed significant decrease in bromocriptine group and haloperidol increased these hormones. Vac. extract decreased significantly the LH and testosterone levels. The coadministration of Vac. extract and bromocriptine decreased LH and testosterone. Coadministration of Vac. extract and haloperidol decreased LH and testosterone levels. These results suggest: dopamine regulates the gonadotroph-leydig cells axis. It appears that Vac. exertes effects through dopaminergic system and other pathways. The findings of this study show we can use Vac. extract for pathological cases of increasing LH and testosterone.
Interesting study. Sounds like vitex may even be an progesterone/estrogen antagonist in certain settings by competitively binding. (It certainly doesn’t look like it has any potency even remotely close to estrogen or progesterone itself)

Im not sure the second study has much relevance. I’m not recommending vitex for PCT.

-Eric
 
Eric Potratz

Eric Potratz

Board Sponsor
Awards
1
  • Established
Do you have any data to back up your assertion that the double bond in the 9th position prevents aromatization of dienolone? The 4,9,11 conjugated system makes it impossible for trenbolone to convert to estrogen but the lack of the 11 double bond in dienolone could allow the electron density of the double bond at the 9-position to actually aid in the formation of the conjugated a-ring system -- i.e. the formatin of estrogen.

Your personal experience of the end effects means nothing in the face of binding data to the contrary. Anecdotal information is useful but does not trump controlled scientific data. Oh, so it has a yellowish hue and burns the musuc membranes -- you just described probably >10,000 unrelated compounds.
Yeah, it should’nt be aromatizing. I’ll have to find a reference for this. Upon a quick search, I pulled this up –

http://www.mesomorphosis.com/articles/llewellyn/trenbolone.htm

AR binding data is the ultimate tell all of a steroids effects eh? Interesting...

-Eric
 
Eric Potratz

Eric Potratz

Board Sponsor
Awards
1
  • Established
You speak as if noone else has anecdotal information -- what you are also lacking is the education and experience in interpretting pharmacological data to formulate a hypothesis that is based on anything but conjecture. You company owners crack me up when you think that somehow you are qualified to make these determinations. If you knew anything about physiology and the action of estrogen you would know that endometrium and breast are very different tissues with very different responses to estrogens and SERMS. When those science type fellows talk about selective estrogen receptor modulators do you realize that they are talking about tissue selectivity and that while tamoxifen is used to fight breast cancer because it acts as an antagonist (with slight partial agonist activity) in the breast that those patients are at an increased risk of endometrial cancer because tamoxifen acts as an agonist in that tissue? You are certainly entitled to your opinion but just realize that it is an unqualified opinion of someone who is trying to defend a product that noone was bashing.
Your right, I don’t know anything about science or SERMs…

BTW, I notice you’re quick to recommend nolva. Here is a piece that some members might want to consider when choosing this drug for gyno related issues -
 
Eric Potratz

Eric Potratz

Board Sponsor
Awards
1
  • Established
I don't mean to be crabby, but my "interesting theory's" are built on 19+ years of personal experience combined with an extensive knowledge of physiology and pharmacology as well as 10+ years in the lab so when someone comes along asserting somethign to be fact based on personal experience alone and question my knowledge, I get a little miffed.

quotes like this one "If you are referring to a stimulus effect at the female hypothalamus/pituitary of estrogen or progesterone, I hope you’re not assuming this stimulatory effect applies to males." don't help.

I’m sorry your miffed and crabby… you shouldn’t be … ya know, with all this free advertising for your book you are getting.

Anyway, Ive made the points I wanted to make.

Good luck.

-Eric
 
sethroberts

sethroberts

Active member
Awards
1
  • Established
Yeah, it should’nt be aromatizing. I’ll have to find a reference for this. Upon a quick search, I pulled this up –

http://www.mesomorphosis.com/articles/llewellyn/trenbolone.htm

AR binding data is the ultimate tell all of a steroids effects eh? Interesting...

-Eric
So you reference an article about trenbolone as a support for dienolone not aromatizing?

AR binding is not the ultimate tell all of a steroids effects, but it means a hell of a lot more than what you anecdotally "feel" from a steroid.
 
sethroberts

sethroberts

Active member
Awards
1
  • Established
Your right, I don’t know anything about science or SERMs…

BTW, I notice you’re quick to recommend nolva. Here is a piece that some members might want to consider when choosing this drug for gyno related issues -
Where was that paper published and who peer reviewed it?
 
sethroberts

sethroberts

Active member
Awards
1
  • Established
I’m sorry your miffed and crabby… you shouldn’t be … ya know, with all this free advertising for your book you are getting.

Anyway, Ive made the points I wanted to make.

Good luck.

-Eric
I have been posting on message boards since 1997 and have only had a book published for the past few months. Obviously my motivation for posting goes beyond advertising my book. Does yours go beyond selling/defending your products? I explained why I get crabby -- people who think that they are qualified to dispute the science because they own a supplement company. Does everyone know what qualifications it takes to start a supplement company and put products onto the market that you ingest?
 
sethroberts

sethroberts

Active member
Awards
1
  • Established
Your right, I don’t know anything about science or SERMs…

BTW, I notice you’re quick to recommend nolva. Here is a piece that some members might want to consider when choosing this drug for gyno related issues -
You may know something about SERMS but you lack the knowledge to understand something as basic as the fact that endometrium and breast are very different when it comes to estrogen response. That is probably the biggest problem on these boards is that people start reading articles in pubmed without the basic understanding of human physiology, pharmacology, pharmacokinetics and chemistry and start to make assertions that are dead wrong. And then they fight for these assertions to the death because their "guru"-hood is built on those assertions. Just like you cannot become a medical doctor by reading medical books, it is difficult if not impossible to become an expert in pharmacology or endocrinology by just reading books or articles - especially if you don't have the baseline education in the topics above.
 
marco wolf

marco wolf

Member
Awards
1
  • Established
sethroberts said,

Pher and superdrol do not convert to estrogen (nor does tren or anadrol) but they do suppress SHBG. SHBG is actually protective against breast tissue growth beyond just sequestering estrogens
Other than keeping dosages and length of cycle reasonable, is there any way of limiting these sides while on a SD-clone?

Or, in your opinion, what would be the best way to run an Mdrol cycle, including PCT?
 
mooch2321

mooch2321

Well-known member
Awards
1
  • Established
sethroberts said,



Other than keeping dosages and length of cycle reasonable, is there any way of limiting these sides while on a SD-clone?

Or, in your opinion, what would be the best way to run an Mdrol cycle, including PCT?
whos seth roberts....
 
Mass_69

Mass_69

Well-known member
Awards
1
  • Established
You may know something about SERMS but you lack the knowledge to understand something as basic as the fact that endometrium and breast are very different when it comes to estrogen response. That is probably the biggest problem on these boards is that people start reading articles in pubmed without the basic understanding of human physiology, pharmacology, pharmacokinetics and chemistry and start to make assertions that are dead wrong...
Seth, according to literature I've read in the past, tamoxifen increases PgRs initially, and then they go back to baseline after around 2 weeks. I was able to dig up a couple of the articles. I do not claim to be an expert in pharmacology or endocrinology, and would be interested in your input regarding my interpretation of these.


(Full article attached)
U. Karck and F. Kommoss
Does tamoxifen change oestrogen and progesterone receptor expression in the endometrium and breast?
Department of Obstetrics and Gynaecology, University of Freiburg, Hugstetter Straβe 55, 79106 Freiburg, Germany
Institute of Pathology, University of Mainz, 55101 Mainz, Germany
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T68-41H3KB0-P&_user=483692&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000022720&_version=1&_urlVersion=0&_userid=483692&md5=0518a335c96ce1eb099609ec32b2dc7c


1: Cancer. 1993 Feb 15;71(4):1266-72.Links
Up-regulation of estrogen receptor by tamoxifen in human breast cancer.
Noguchi S, Motomura K, Inaji H, Imaoka S, Koyama H.
Department of Surgery, Center for Adult Diseases, Osaka, Japan.
http://www.ncbi.nlm.nih.gov/pubmed/8382104
 

Attachments

Dragon13

Dragon13

Active member
Awards
1
  • Established
I have a seemingly simple question in all this that I believe is the crux of the whole argument (at least it is for me, as I've researched this quite a bit). Maybe Seth can answer it.

Does binding the progesterone receptor have any effect whatsoever on prolactin levels?

Or even more simply: other than a concurrent rise in estrogen, what other stimuli can raise prolactin?

If anyone can answer these, I think I'll have a pretty good grasp of what happens with so-called prolactin gyno.
 
Eric Potratz

Eric Potratz

Board Sponsor
Awards
1
  • Established
You may know something about SERMS but you lack the knowledge to understand something as basic as the fact that endometrium and breast are very different when it comes to estrogen response. That is probably the biggest problem on these boards is that people start reading articles in pubmed without the basic understanding of human physiology, pharmacology, pharmacokinetics and chemistry and start to make assertions that are dead wrong. And then they fight for these assertions to the death because their "guru"-hood is built on those assertions. Just like you cannot become a medical doctor by reading medical books, it is difficult if not impossible to become an expert in pharmacology or endocrinology by just reading books or articles - especially if you don't have the baseline education in the topics above.
Anyway…

You recommended Nolva for progestin based gyno. I’m sorry, but in my experience this doesn’t work. I’ve provided my recommendations for something that does work. No need for personal insults…
 
sethroberts

sethroberts

Active member
Awards
1
  • Established
And what peer reviewed journal published “anabolic pharmacology”?
Very true. However, I did not reference my book as support at any point in this discussion. You referenced a rather silly article written by yourself and posted on your company web site. Sorry if that doesn't carry much weight in my opinion. Nor does your personal experience.
 
sethroberts

sethroberts

Active member
Awards
1
  • Established
Anyway…

You recommended Nolva for progestin based gyno. I’m sorry, but in my experience this doesn’t work. I’ve provided my recommendations for something that does work. No need for personal insults…
Show me one shred of evidence that stimulation of the progesterone receptor causes gynecomastia.
 
sethroberts

sethroberts

Active member
Awards
1
  • Established
Seth, according to literature I've read in the past, tamoxifen increases PgRs initially, and then they go back to baseline after around 2 weeks. I was able to dig up a couple of the articles. I do not claim to be an expert in pharmacology or endocrinology, and would be interested in your input regarding my interpretation of these.


(Full article attached)
U. Karck and F. Kommoss
Does tamoxifen change oestrogen and progesterone receptor expression in the endometrium and breast?
Department of Obstetrics and Gynaecology, University of Freiburg, Hugstetter Straβe 55, 79106 Freiburg, Germany
Institute of Pathology, University of Mainz, 55101 Mainz, Germany
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T68-41H3KB0-P&_user=483692&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000022720&_version=1&_urlVersion=0&_userid=483692&md5=0518a335c96ce1eb099609ec32b2dc7c


1: Cancer. 1993 Feb 15;71(4):1266-72.Links
Up-regulation of estrogen receptor by tamoxifen in human breast cancer.
Noguchi S, Motomura K, Inaji H, Imaoka S, Koyama H.
Department of Surgery, Center for Adult Diseases, Osaka, Japan.
http://www.ncbi.nlm.nih.gov/pubmed/8382104
Those were the papers I was referring to when I mentioned in one of my posts that tamoxifen may cause a slight upregulation or no change in progesterone receptor.
 
marco wolf

marco wolf

Member
Awards
1
  • Established
sethroberts said,

Pher and superdrol do not convert to estrogen (nor does tren or anadrol) but they do suppress SHBG. SHBG is actually protective against breast tissue growth beyond just sequestering estrogens
marco asked:

Other than keeping dosages and length of cycle reasonable, is there any way of limiting these sides while on a SD-clone?

Or, in your opinion, what would be the best way to run an Mdrol cycle, including PCT?
I'm not trying to put you on the spot, or anything, but you've stated that you're "not a fan" of AI's. I was wondering what you would recommend instead of AI's, if anything at all.
 
sethroberts

sethroberts

Active member
Awards
1
  • Established
I have a seemingly simple question in all this that I believe is the crux of the whole argument (at least it is for me, as I've researched this quite a bit). Maybe Seth can answer it.

Does binding the progesterone receptor have any effect whatsoever on prolactin levels?

Or even more simply: other than a concurrent rise in estrogen, what other stimuli can raise prolactin?

If anyone can answer these, I think I'll have a pretty good grasp of what happens with so-called prolactin gyno.
There are quite a few papers showing progesterone to reduce prolactin levels -- likely through its suppressive effects on estrogen receptor activation. I pasted abstracts from a couple below. Even medroxyprogesterone, a very potent porgesterone, causes a decease in prolactin receptor levels.

Drugs that interfere with the production or release of dopamine. Antipsychotic medications are well known for causing increased prolactin levels.


1: Biol Reprod. 1988 Dec;39(5):1067-73. Links
Antagonism of estrogen-induced prolactin release by progesterone.Brann DW, Rao IM, Mahesh VB.
Department of Physiology and Endocrinology, Medical College of Georgia, Augusta 30912-3000.

Previous work from our laboratory has shown that during the process of nuclear occupancy of the progesterone receptor complex (1-2 h), nuclear estradiol receptors of the anterior pituitary are depleted. The purpose of this study was to determine whether the depletion of nuclear estradiol receptors by progesterone had functional biological significance. The ovariectomized (26 days of age) immature rat was used as the model for analysis of this question. The ability of estradiol to release prolactin from the anterior pituitary was the function chosen to determine the biological significance of the progesterone and estradiol interactions. In response to estradiol exposure (2 micrograms/rat), prolactin release reached peak values from 8 h to 12 h and returned to control levels by 24 h. A second injection of estradiol 13 h after the initial injection stimulated a second increase in serum prolactin at 25 h. This model of two injections of estradiol 13 h apart served to provide adequate levels of anterior pituitary progesterone receptors and elevated serum prolactin levels upon which superimposed progestin modulation could be examined. A single injection of progesterone (0.8 mg/kg BW) 1 h before the second estradiol injection blocked the increase in serum prolactin. This action was a receptor-mediated event because progesterone had no effect without estrogen priming or when the progesterone antagonist RU486 was used. Finally, when the interval between the progesterone and second estradiol injection was extended to 4 h, a time period when progesterone does not deplete pituitary nuclear estrogen receptors, the estrogen-induced increase in serum prolactin was not blocked.(ABSTRACT TRUNCATED AT 250 WORDS)

1: Pharmacol Res Commun. 1988 Aug;20(8):719-30.Links
Effects of medroxyprogesterone acetate on serum prolactin levels and liver prolactin binding capacity in the rat.Muccioli G, Racca S, Ricci Gamalero S, Di Carlo F.
Institute of Pharmacology, Faculty of Medicine, University of Turin, Italy.

Modifications in liver prolactin (PRL) receptor levels and serum PRL concentration induced by administration of medroxyprogesterone acetate (MPA) were investigated in rats of both sexes. MPA induced a reduction both of the levels of PRL in the serum and of liver PRL receptors in the female rat. The reduction of the number of PRL receptors caused by MPA was rapid and almost complete after 10 days of treatment and appeared earlier than that of serum PRL levels. Furthermore the MPA-induced decrease in PRL receptors was specific, since insulin binding to the same liver membranes was not affected. MPA given simultaneously with oestradiol (which increases both the number of liver PRL receptors and the serum PRL levels in the male rats) was able to counteract the increase in PRL binding induced by oestradiol. On the contrary, the oestrogen-induced increase in serum PRL was not affected by MPA treatment. Similar results were obtained using tamoxifen, a well known antioestrogenic drug. In conclusion, our results show that the reduction of PRL receptor levels induced by MPA in rat liver is specific, not correlated to serum PRL concentration, and seems to depend on the antioestrogenic activity of the drug.
 
nunes

nunes

Well-known member
Awards
1
  • Established
I got to say that I agree with Seth in everything he says, it make a lot a sense and for my research , experience and readings on anabolics its all true
reps and I`M going to the store and buy the book, I`ll pay a lot in taxes but what the hell its well worth
 

Similar threads


Top